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Summary 
The rapid emergence of published data regarding drug enantiomers should be reflected in the use of 
racemic drugs in the clinical setting. The Department of Pharmacy, University of Malta, becoming 
aware of the problems created by the unknowledgeable use of racemic drugs has conducted two studies. 
The first study data focused on quantifying the number of chiral drugs in the Maltese National 
Formulary, being administered as racemic mixtures, in order to provide a better basis for purchase 
specifications when procuring drugs. The second study analyzed attitudes by physicians towards drug 
chirality. 
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Introduction 
The realization ofthe importance of stereochemistry 
in pharmacology and therapeutic action has a valid 
contribution to make in the development of safer 
and more effective medicine1. Such new knowledge 
should be reflected in the use of racemic drugs. 
Both the scientific and popular press have focused 
their attention on the upsurge in stereoisomeric 
interest-somewith'alarmist'headlines2,3,4,5,6,7. This 
should provide a better basis fo~ purchase 
specifications of drugs and the promotion of 
stereoisomeric awareness amongst authorities and 
members of the health care team. 
Stereoisomeric Drugs 
Racemates are 50 I 50 mixtures of the left and right-
handed forms or enantiomers of compounds, whose 
molecular structure lack symmetry because the 
central carbon atom is surrounded by four different 
atoms or groups of atoms. This phenomenon is 
referred to as chirality - derived from the Greek 
word' cherios' which signifies handedness i.e. being 
left or right handed. Enantiomers are mirror images 
and can be distinguished from the way they rotate 
polarized light, hence the (+)I (-) or (d) I (1) 
nomenclature. The accepted nomenclature today is 
the (R) I (S) system which is related to the Cahn-
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Ingold-Prelog Convention7. For example labetolol 
is only one of a number of chiral drugs with two 
chiral centers (figure 1). Often one isomer is 
therapeutically active but this does not mean that 
the other is inactive. The therapeutically nonactive 
form in a racemate may be regarded as an impurity 
but it may not be a passive component of the drug 
mixture. It may be an agonist, or an antagonist, or 
it may have actions on other receptors, resulting in 
either unwanted side effects or contributing to 
overall drug efficacy. In addition, its metabolites 
may also be active or toxic2• 
Figure 1: The chemical structure of labetolol. (*chiral 
centres). 
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Perhaps the most dramatic example is 
highlighted by the thalidomide tragedy. This 
drug was marketed during the 1960's as a 
sedative, and it was widely used by pregnant 
women, many of whom later gave bi:th to 
deformed children. Thalidomide was 
administered as a racemic mixture of its two 
optical isomers. Too late, did subsequent 
research show that it was only the sinistral (-)-
isomer, and not the (+)-isomer, which had a 
teratogenic effect on rat embryos, producing 
the same birth defect as those of the 
thalidomide children in the early 1960's 8. 
About 40% of synthetic drugs are chiral. Mason9 
has calculated that more than 80% of the synthetic 
chiral pharmaceuticals which appear in the United 
States Pharmacopoeia are administered as their 
racemates i.e. as equal mixtures of relatively' active' 
and 'inactive' isomers. Terms such as isomeric 
ballast2 and composite chiral drugs (CCDs)10 have 
now become commonplace. But unfortunately 
medical curricula still deal with stereochemistry as 
an area to be investigated only when referring to 
the biochemistry of amino acids and sugars. Few 
teaching and/ or reference medical books ever 
mention stereochemistry and its significancel. 
Methods 
Studyl 
A comprehensive database was compiled of a[ drugs 
in the updated version of the Maltese National 
Formulary, subclassified as synthetic, semisynthetic 
and natural, chiral and achiral and including 
stereochemical properties, efficacy, risk benefit, and 
cost effectiveness of single isomers of drug racemates 
(if available). Standard textbooks suchasMartindale11, 
British Pharmacopoeia12 and Therapeutic Drugs13 were 
used to determine the structure of each drug and 
whether it was available as single enantiomer ::>r not. 
Study 2 
A survey was conducted on a randomized 
sample of registered physicians in Malta in 
order to review their attitudes towards inherent 
problems associated with the use of racemic 
drugs. The thesis behind the study expounded 
on Tucker's presupposition that most clinicians 
are unlikely to 'know their right hand from 
their left'3 . 
Results 
Study 1 
From an in-depth scrutiny, it was revealed that 
approximately 47% of drugs in the Maltese 
National Formulary classified as 
semisynthetic/natural; 99% of these had at 
least one chiral center but nearly all were 
available as one isomer, while more than 60% 
of synthetic chiral drugs were purchased as 
racemates (figure 2, figure 3). The distribution 
of racemic drugs amongst different 
pharmacological categories was found to be 
highly uneven. The appearance of a racemate 
in the field of peptides or hormones was 
exceptional. 
The study also included a separate review of 
geometric isomers, such as tamoxifen and 
phytomenadione, which had previously been 
pooled with chiral isomers. These made up about 
3%ofthetotalnumberofdrugs(figure4). Prcblems 
associated with the use of the wrong isomer of 
tamoxifen had already been described im our 
hospitaF4· 
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Figure 2: The chirality of drugs in the Maltese Formulary. 
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Figure 3: A comparison of the stereoisomeric configuration of organic drugs in the Maltese Formulary. 
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Figure 4: Subdivision of organic drugs found in the Maltese Formulary. 
These results were consistent with previously 
published data 15,16,17· Most racemic drugs are now 
under investigation and the pharmacokinetic and 
pharmacodynamic differences studied. Only a few 
synthetic chiral drugs e.g. naprosyn, timolol, 
methyldopa, and dextromethorphan are already 
available as a single enantiomer1,18,19. 
A review of published literature was undertaken to 
evaluate when the use of single isomers is 
recommended. References were found to indicate 
large pharmacological differences in quite a large 
number of chiral drugs19. It has been reported that it 
is (d)-propranolol which acts as the beta-
adrenoreceptor agent, but both stereoisomers 
contribute to its local anesthetic and histamine 
releasing action2°. (d)-Ketamine is predominantly a 
hypnotic and an analgesic, whereas the (I)-isomer is 
the main source of its unwanted side-effects 21 . The 
therapeuticindexofdisopyramidecould be improved 
by eliminating the (-)-isomer. This enantiomer is a 
less potent anti-arrhythmic then the (+)-form, anditis 
mostly responsible for the heart failure precipitated 
by administration of the racemic drug, through its 
marked negative inotropic effect 22· 
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Care must be exerted if decisions are taken to 
change from a racemate to an isomer. Although the 
(S)-isomer of warfarin is about 3-5 times as potent 
as its a:1tipode, switching from the racemate to the 
(S)-isomer, would necessitate a reduction in the 
dose. There would be no change in therapeutic 
index and this would precipitate a specific set of 
potent.al drug interactions23. On the contrary, the 
greater intrinsic anti-inflammatory potency of (S)-
ibuprofen is compensated to some extent when 
using the racemate by metabolic inversion of the 
less active (R)-form and in fact approximately 60% 
of an oral dose of (R)-ibuprufen is inverted to the 
(S)-enantiomer 24. Drugs available as single isomers 
were often prohibitively expensive compared to 
their racemic counterparts. Cost effectiveness of 
the use of single isomers is still to be determined. 
The rerults and recommendations of this study are 
to be :,.anded over to the Maltese Drugs and 
Therapeutic Committee, which is responsible for 
updating the Maltese National formulary and also 
to the Drug Information Unit, at St. Luke's Hospital, 
the ma:or teaching hospital in Malta. 
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Study 2 
A survey was made among a randomized sample 
of registered physicians in Malta. Over 320 
questionnaires were sent by post. There was a 33% 
response, consistent with previous surveys of this 
type and it reflected the actual population of Maltese 
physicians. Nearly 40% of these graduated 5-10 
years ago (figure 5). The respondents were mostly 
housemen (21%) or consultants (23.1% ). 28% worked 
inthecommunity,while10%wereretired(Figure 6); 
66.2% regularly attended continuing education 
courses. 
46.77% 
• less than 5 yrs • 20-30 yrs 5-10 yrs D . 30-40 yrs 
• 10-15 yrs Cl more than 40 yrs 0 15-20 yrs 
Figure 5: Registration year of physicians who responded. 
28.80% 
9.92% 
houseman • community practice senior assistant 0 researcher 
• consultant LJ retired 0 director 
Figure 6: Professional status ofphysicians who responded. 
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When questioned about the terms stereoisomerism 
and chirality, 52% said that this topic had only been 
mentioned briefly in their undergraduate years, 
mostly in their biochemistry and pharmacology 
courses. Less than 10% had heard the terms in 
postgraduate training or continuing education 
courses (Figure 7). Two doctors referred to the use 
of (-) folic acid and importance of stereoisomerism 
in legal definitions of drugs of abuse. 83% had 
never read any information about drug chirality 
while 11% had read at least one article in the medical 
literature. Only in 2 cases, had the subject been 
mentioned by a drug medical representative 
(Figure 8). 
Were the terms Stereoisomerism or Chirality 
ever mentioned ? 
Yes 
Undergraduate Years 52.00% 
Postgraduate Years 9.88% 
Continuing Education 5.82% 
Figure 7: Physicians' knowledge of chirality. 
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No 
48.00% 
90.12% 
94.18% 
1.31% 
1.53% 
1.98% 
1.02% 
• 0 
• r::::r t:::£:1 
drug medical representative 
medical journal and medical rep 
other 
Figure 8: Physicians' sources ofinformationonchirality. 
-
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43% were of the opinion thatthese problems should 
be tackled by physicians, pharmacists and 
biochemists, and some even suggested that it should 
be tackled by the local authorities and the 
pharmaceutical industry (Figure 9). It was 
interesting to note that nearly all were grateful for 
the information we had given them and 92% wanted 
to learn more about the subject, especially by 
receiving more information at home or attending a 
lecture. Some respondents were keen to participate 
in continuing education sessions on the subject 
(Figure 10). Only a small percent of physicians 
(<13%) questioned were actually aware of the 
problems associated with administering drug 
racemates (Figure 11). Nearly all the doctors found 
the subject very interesting and even showed their 
professional gratitude for the study. 
35.86% 
43.01 
• no answer • physicians 
E3 
• pharmacists D biochemists D 
4.14% 
2.18% 
4.34% 
1.54% 
physicians and 
pharmacists 
other eg, industry, 
regulatory bodies 
all of the above 
Figure 9: Membersofthehealthcareteamwho,according 
to physicians, should tackle the problem. 
Interested in learning more 
about drug chirality 
More literature at home 
92.26% 
62.06% 
Read more about it in meclical journals 27.52% 
Attend organised lectures 15.72% 
Part of continuing education course 33.31% 
Figure 10: Respondents' interest to further knowledge. 
• very familiar 
quite familiar 
B slightly familiar 
D never heard of them 
Figure 11: Physicians' familiarity with the terms 
stereoisomerism and chirality. 
Conclusion 
Most ehiral synthetic drugs are still widely used as 
racemic mixtures in the clinical setting even if 
published literature suggests pharmacological 
differences. It can be argued that the majority of 
physicians are still unaware of problems associated 
with adtninistering racemic drugs, but it appears 
from this st1:1dy that most are willing to learn more. 
Several regulatory agencies have issued guide-
lines25,26,27,28· Perhaps it is wrong to start a witch 
hunt for racemic drugs which are already 
marketed29, but it can be predicted that a full clinical 
study of the pharmacological and toxicological 
effects of both enantiomers of any new chiral drug, 
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may be required soon, in order to obtain 
authorization for marketing the drug as a racemic 
mixture 30(Figure 12). Only 5 of the 12 leading 
chiral drugs in the USA are being sold as single 
isomers. Some drugs are already being developed 
as the pure enantiomers from existing composite 
chiral drugs with still valid patents. These include 
S-atenolol, R-salbutamol, S-terfenadine, R-
ketoprofen, RR-formoterol, S-fluoxetine, S-
ondansteron, R-salmeterol, S-fluriprofen and S-
ibuprofen. Some drugs such as fenfluramine, are 
being sold simultaneously as a single isomer 
(AdifexR) and as a racemate (PonderaxR). The less 
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cardiotoxic R-isomer of verapamil is being 
investigated for the prevention of MDR in cancer 
chemotherapy. 
Stereoisomeric pharmacovigilance on the use of 
racemic drugs should be encouraged and the new 
EU and FDA regulations translated to the clinical 
setting31 but it appears that, so far, little has been 
done. In very few ofthe recommended textbooks of 
pharmacology, pharmacokinetics and toxicology, 
are the principles of stereoselectivity properly 
described or even mentioned in the index, although 
some specialized pharmacy journals have included 
the subject in continuing education articles for their 
readers32,33. Financial restraints often dictate health 
policies and procurement procedures. However, 
stereoisomeric pharmacovigilance on the use of 
racemic drugs in hospital formularies must be 
encouraged. Appropriate education is needed if 
choices between racemates and single isomers are 
to be presented. Drug therapy can only gain from 
the fruitful discussions on the continual assessment 
of 'looking glass drugs', and to Tucker's challenge 
'Does the left hand know what the right hand is 
doing, we ask ' Does the left hand want to know 
what the right hand is doing'. The answer from 
Malta is an unequivocal grateful'yes'. 
Arguments in favour of marketing drugs as 
pure enantiomers 
• Improved less complex and more selective 
pharmacological profile 
• Better therapeutic index 
• Less complex pharmacokinetics 
• Less complex concentration-response 
relationships particularly in relation to 
therapeutic drug monitoring 
Arguments against marketing drugs as 
pure enantiomers 
• Cost of development 
• Cost of production 
Figure 12: Enantiomers or Racemates?30 
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